In vitro Activity of Ceftaroline Against Isolates of Gram-Positive Bacteria from Patients with Bloodstream Infections Collected as a Part of ATLAS Between 2017 and 2020
Marie Kempf,1,2 Francis F Arhin,3 Alona Kuraieva,4 Eric Utt5 1Laboratory of Bacteriology, University Hospital Angers, Angers, France; 2INCIT, Inserm, CHU Angers, Univ Angers, Nantes Université, Angers, F-49000, France; 3Pfizer Inc, Kirkland, Quebec, Canada; 4Pfizer Inc, New York, NY, USA; 5Pfizer In...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2024-01-01
|
| Series: | Infection and Drug Resistance |
| Subjects: | |
| Online Access: | https://www.dovepress.com/in-vitro-activity-of-ceftaroline-against-isolates-of-gram-positive-bac-peer-reviewed-fulltext-article-IDR |
| _version_ | 1797335753054748672 |
|---|---|
| author | Kempf M Arhin FF Kuraieva A Utt E |
| author_facet | Kempf M Arhin FF Kuraieva A Utt E |
| author_sort | Kempf M |
| collection | DOAJ |
| description | Marie Kempf,1,2 Francis F Arhin,3 Alona Kuraieva,4 Eric Utt5 1Laboratory of Bacteriology, University Hospital Angers, Angers, France; 2INCIT, Inserm, CHU Angers, Univ Angers, Nantes Université, Angers, F-49000, France; 3Pfizer Inc, Kirkland, Quebec, Canada; 4Pfizer Inc, New York, NY, USA; 5Pfizer Inc, Groton, CT, USACorrespondence: Eric Utt, Pfizer Inc, Gorton, CT, 06340, USA, Tel +1 860 9174808, Email eric.a.utt@pfizer.comPurpose: To assess the in vitro activity of ceftaroline and a panel of comparator agents against isolates of Gram-positive bacteria, including Staphylococcus aureus, Streptococcus pneumoniae, β-hemolytic streptococci, and coagulase-negative staphylococci (CoNS) from blood collected in Africa and Middle East (AfME), Asia Pacific (APAC), Europe, Latin America (LATAM), and North America from 2017 to 2020 as a part of the Antimicrobial Testing Leadership and Surveillance (ATLAS) program.Methods: Susceptibility and minimum inhibitory concentration were determined using broth microdilution for all antimicrobial agents by a central reference laboratory according to the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines.Results: Ceftaroline showed good activity (susceptibility ≥ 89.8%, MIC90 0.008– 2 mg/L) against all Gram-positive isolates tested. All isolates of methicillin-susceptible S. aureus, penicillin-susceptible S. pneumoniae, S. agalactiae, S. dysgalactiae, and S. pyogenes were susceptible to ceftaroline (MIC90 0.008– 0.25 mg/L). Ceftaroline susceptibility for MRSA isolates was 89.8% globally (MIC90 2 mg/L). Among the comparator agents, all isolates were susceptible to vancomycin, except S. epidermis (susceptibility, 99.9%). Among other agents, daptomycin, linezolid, and tigecycline showed potent activity (susceptibility ≥ 97.9%, MIC90 0.03– 2 mg/L) against all isolates tested.Conclusion: Ceftaroline showed potent in vitro activity against global bloodstream isolates of Gram-positive bacteria collected between 2017 and 2020. Monitoring and surveillance of global as well as regional longitudinal trends of resistance rates among Gram-positive isolates causing bloodstream infections are important to limit the spread of AMR, establish stewardship measures, and manage and appropriately treat infections.Keywords: ATLAS, bloodstream infections, ceftaroline, Gram-positive bacteria, surveillance |
| first_indexed | 2024-03-08T08:42:57Z |
| format | Article |
| id | doaj.art-0c10cd75e323415fae66e8290d4dc05e |
| institution | Directory Open Access Journal |
| issn | 1178-6973 |
| language | English |
| last_indexed | 2024-03-08T08:42:57Z |
| publishDate | 2024-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Infection and Drug Resistance |
| spelling | doaj.art-0c10cd75e323415fae66e8290d4dc05e2024-02-01T17:59:26ZengDove Medical PressInfection and Drug Resistance1178-69732024-01-01Volume 1734335490072In vitro Activity of Ceftaroline Against Isolates of Gram-Positive Bacteria from Patients with Bloodstream Infections Collected as a Part of ATLAS Between 2017 and 2020Kempf MArhin FFKuraieva AUtt EMarie Kempf,1,2 Francis F Arhin,3 Alona Kuraieva,4 Eric Utt5 1Laboratory of Bacteriology, University Hospital Angers, Angers, France; 2INCIT, Inserm, CHU Angers, Univ Angers, Nantes Université, Angers, F-49000, France; 3Pfizer Inc, Kirkland, Quebec, Canada; 4Pfizer Inc, New York, NY, USA; 5Pfizer Inc, Groton, CT, USACorrespondence: Eric Utt, Pfizer Inc, Gorton, CT, 06340, USA, Tel +1 860 9174808, Email eric.a.utt@pfizer.comPurpose: To assess the in vitro activity of ceftaroline and a panel of comparator agents against isolates of Gram-positive bacteria, including Staphylococcus aureus, Streptococcus pneumoniae, β-hemolytic streptococci, and coagulase-negative staphylococci (CoNS) from blood collected in Africa and Middle East (AfME), Asia Pacific (APAC), Europe, Latin America (LATAM), and North America from 2017 to 2020 as a part of the Antimicrobial Testing Leadership and Surveillance (ATLAS) program.Methods: Susceptibility and minimum inhibitory concentration were determined using broth microdilution for all antimicrobial agents by a central reference laboratory according to the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines.Results: Ceftaroline showed good activity (susceptibility ≥ 89.8%, MIC90 0.008– 2 mg/L) against all Gram-positive isolates tested. All isolates of methicillin-susceptible S. aureus, penicillin-susceptible S. pneumoniae, S. agalactiae, S. dysgalactiae, and S. pyogenes were susceptible to ceftaroline (MIC90 0.008– 0.25 mg/L). Ceftaroline susceptibility for MRSA isolates was 89.8% globally (MIC90 2 mg/L). Among the comparator agents, all isolates were susceptible to vancomycin, except S. epidermis (susceptibility, 99.9%). Among other agents, daptomycin, linezolid, and tigecycline showed potent activity (susceptibility ≥ 97.9%, MIC90 0.03– 2 mg/L) against all isolates tested.Conclusion: Ceftaroline showed potent in vitro activity against global bloodstream isolates of Gram-positive bacteria collected between 2017 and 2020. Monitoring and surveillance of global as well as regional longitudinal trends of resistance rates among Gram-positive isolates causing bloodstream infections are important to limit the spread of AMR, establish stewardship measures, and manage and appropriately treat infections.Keywords: ATLAS, bloodstream infections, ceftaroline, Gram-positive bacteria, surveillancehttps://www.dovepress.com/in-vitro-activity-of-ceftaroline-against-isolates-of-gram-positive-bac-peer-reviewed-fulltext-article-IDRatlasbloodstream infectionsceftarolinegram-positive bacteriasurveillance |
| spellingShingle | Kempf M Arhin FF Kuraieva A Utt E In vitro Activity of Ceftaroline Against Isolates of Gram-Positive Bacteria from Patients with Bloodstream Infections Collected as a Part of ATLAS Between 2017 and 2020 Infection and Drug Resistance atlas bloodstream infections ceftaroline gram-positive bacteria surveillance |
| title | In vitro Activity of Ceftaroline Against Isolates of Gram-Positive Bacteria from Patients with Bloodstream Infections Collected as a Part of ATLAS Between 2017 and 2020 |
| title_full | In vitro Activity of Ceftaroline Against Isolates of Gram-Positive Bacteria from Patients with Bloodstream Infections Collected as a Part of ATLAS Between 2017 and 2020 |
| title_fullStr | In vitro Activity of Ceftaroline Against Isolates of Gram-Positive Bacteria from Patients with Bloodstream Infections Collected as a Part of ATLAS Between 2017 and 2020 |
| title_full_unstemmed | In vitro Activity of Ceftaroline Against Isolates of Gram-Positive Bacteria from Patients with Bloodstream Infections Collected as a Part of ATLAS Between 2017 and 2020 |
| title_short | In vitro Activity of Ceftaroline Against Isolates of Gram-Positive Bacteria from Patients with Bloodstream Infections Collected as a Part of ATLAS Between 2017 and 2020 |
| title_sort | in vitro activity of ceftaroline against isolates of gram positive bacteria from patients with bloodstream infections collected as a part of atlas between 2017 and 2020 |
| topic | atlas bloodstream infections ceftaroline gram-positive bacteria surveillance |
| url | https://www.dovepress.com/in-vitro-activity-of-ceftaroline-against-isolates-of-gram-positive-bac-peer-reviewed-fulltext-article-IDR |
| work_keys_str_mv | AT kempfm invitroactivityofceftarolineagainstisolatesofgrampositivebacteriafrompatientswithbloodstreaminfectionscollectedasapartofatlasbetween2017and2020 AT arhinff invitroactivityofceftarolineagainstisolatesofgrampositivebacteriafrompatientswithbloodstreaminfectionscollectedasapartofatlasbetween2017and2020 AT kuraievaa invitroactivityofceftarolineagainstisolatesofgrampositivebacteriafrompatientswithbloodstreaminfectionscollectedasapartofatlasbetween2017and2020 AT utte invitroactivityofceftarolineagainstisolatesofgrampositivebacteriafrompatientswithbloodstreaminfectionscollectedasapartofatlasbetween2017and2020 |